Who
Andrew John Partridge
Chief Growth Officer
Company insider
Files Form 4 as: Chief Growth Officer, Grail; EVP & Chief Commercial Officer, Turning Point Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $1.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 13 Jul 2020
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $1.2M7,873 at $146.39 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $91K1,491 at $61.08 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Sold | $91K1,491 at $61.08 | filing |
| 9 Feb 2022filed 11 Feb 2022 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code A | —58,600 at $0.00 | filing |
| 9 Feb 2022filed 11 Feb 2022 | Turning Point Therapeutics | SEC FORM 4 Sold | $8,022221 at $36.30 | filing |
| 9 Feb 2022filed 11 Feb 2022 | Turning Point Therapeutics | SEC FORM 4 Code A | —16,283 at $0.00 | filing |
| 14 Jul 2021filed 15 Jul 2021 | Turning Point Therapeutics | SEC FORM 4 Sold | $140K1,869 at $74.90 | filing |
| 8 Feb 2021filed 10 Feb 2021 | Turning Point Therapeutics | SEC FORM 4 Code A | —2,136 at $0.00 | filing |
| 8 Feb 2021filed 10 Feb 2021 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code A | —9,733 at $0.00 | filing |
| 13 Jul 2020filed 14 Jul 2020 | Turning Point Therapeuticsoption or derivative | SEC FORM 4 Code A | —127,500 at $0.00 | filing |
| 13 Jul 2020filed 14 Jul 2020 | Turning Point Therapeutics | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
News
GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 20,000 Shares of StockGRAL · dailypolitical.com · 17 Oct 2026Jim Cramer Breaks Down the Stakes in Detail as GRAIL (GRAL) Awaits Its Next Big DecisionGRAL · insidermonkey.com · 10 Oct 2026Head to Head Review: Gilead Sciences (NASDAQ:GILD) versus GRAIL (NASDAQ:GRAL)GRAL · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Andrew John Partridge; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.